Diffuse Large B-cell Lymphoma
Conditions
Keywords
diffuse large b cell lymphoma, newly diagnosed
Brief summary
Newly diagnosed DLCL patients will have baselne FDG-PET as part of initial staging (PET-1). Patients will then undergo 2 cycles of chemotherapy with R/CHOP. 14 to 21 days following cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessment will be performed, including CT scans of the chest, abdomen and pelvis and FDG-PET scan (PET-3).
Interventions
None listed
Sponsors
Weill Medical College of Cornell University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T cell rich B cell and anaplastic B cell lymphoma * Patients must have received no prior anti-lymphoma therapy. * Age \>18 years. * Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Patients who have known HIV infection. * Patients who are, in the opinion of their treating oncologist, unable to undergo R/CHOP chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluating the predictive value of a positive PET scan early in the course of standard chemotherapy | after 2 cycles of chemotherapy |
Countries
United States
Outcome results
None listed